Yuanzhang Fang

500 Dongchuan Rd
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Retraction Note: Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.

Retraction Note: Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.

Journal: Nature communications

Published: July 07, 2026

Retraction Note: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Retraction Note: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Journal: Nature communications

Published: June 29, 2026

Amendment to Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.

Amendment to Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.

Journal: The Journal of clinical investigation

Published: May 01, 2026

Amendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.

Amendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.

Journal: The Journal of clinical investigation

Published: May 01, 2026

Retraction for Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.

Retraction for Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.

Journal: The Journal of clinical investigation

Published: January 16, 2026

Retraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.

Retraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.

Journal: The Journal of clinical investigation

Published: January 16, 2026

Author Correction: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.

Author Correction: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.

Journal: Nature biomedical engineering

Published: August 30, 2023

In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy.

In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy.

Journal: Nature communications

Published: July 20, 2022

Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.

Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.

Journal: The Journal of clinical investigation

Published: December 11, 2020

Metabolic interventions: A new insight into the cancer immunotherapy.

Metabolic interventions: A new insight into the cancer immunotherapy.

Journal: Archives of biochemistry and biophysics

Published: July 02, 2020

MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.

MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.

Journal: The Journal of clinical investigation

Published: June 01, 2020

An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.

An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.

Journal: Nature biomedical engineering

Published: May 07, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026